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Is nanomedicine an area with the promise that its proponents claim? Professors Gabriel Aeppli and Quentin Pankhurst explore the issues in light of the new London Centre for Nanotechnology (LCN) -a joint enterprise between Imperial College and University College London -opened on November 7, 2006. The center is a multidisciplinary research initiative that aims to bridge the physical, engineering and biomedical sciences. In this interview, Professor Gabriel Aeppli, LCN co-Director, and Deputy Director Professor Quentin Pankhurst discuss the advent and future role of the LCN with Nanomedicine's Morag Robertson. Professor Aeppli was formerly with NEC, Bell Laboratories and MIT and has more than 15 years' experience in the computer and telecommunications industry. Professor Pankhurst is a physicist with more than 20 years' experience of working with magnetic materials and nanoparticles, who now works closely with clinicians and medics on innovative healthcare applications. He also recently formed the new start-up company Endomagnetics Inc.
How would you summarize your current research interests and those of the LCN as a whole? GA: The center's research interests are extremely broad and include not only healthcare but information technology and environmental technologies. Current research at the healthcare front focuses on exploiting the tremendous capabilities that silicon technologies have brought us over the past 20 years and exporting these into medical research laboratories and clinical settings. At the same time, another set of capabilities that has arisen relates to the synthesis and functionalization of nanoparticles, which, at the LCN, is embodied by Professor Pankhurst's work.
QP: My focus is on making and using biocompatible magnetic dyes. Working with magnetic particles really boils down to taking advantage of three key features: the ability to heat them, to move them and to sense them. With heating, we are exploring routes to developing magnetic hyperthermia, which has the potential for localized heating as a way of treating cancers, for example. We are working with oncologists at the Royal Free Hospital and also University College Hospital to devise methods to deliver magnetic particles to tumors and then to heat them. We are using magnetic actuation -moving the particles around -to explore drug delivery and also the delivery of stem cells for regenerative therapy. With the stem cells, we have started with a case study of atherosclerosis since our colleagues at the Institute of Child Health have an animal model of injury-induced atherosclerosis that will allow us to quantify the technique. Looking ahead though, the really exciting thing could be to address cardiovascular disease in a similar way.
On the sensing side, we founded a spin-out company -Endomagnetics Inc. -in February 2006. Currently, we are commercializing a handheld probe -you could think of it as being something like a hand-held magnetic resonance imaging (MRI) scanner -that we call the SentiMAG™, and other applications are in the pipeline, such as the FerriMAG™, which is used to identify iron overload in the liver and the heart. The SentiMAG allows the detection of the presence of a magnetic dye as it tracks from an injection site in a breast cancer tumor down into the lymphatic system. It allows the nonspecific take-up of the dye in the lymph nodes, particularly the sentinel lymph nodes, to be tracked. We are working closely with surgeons and MRI specialists at University College Hospital and the Institute of Cancer Research to make this a reliable and useful tool in the hands of surgeons, both before and after incision. Locating the node is very important because if a surgeon is able to locate the sentinel node then he/she can remove that node, look at it under a microscope and determine quickly whether or not the cancer has spread. If it has not spread, then the operation is over and the patient does not need to undergo the current standard approach, an axillary node clearance, which is very painful.
What do you feel are the main roles and aims for the LCN, and what makes the center different? GA: Our goals are pretty simple -start up companies with billion-dollar sales and a few Nobel prizes! More realistically, the aim is to produce highly influential science that has medical applications -technologies that have uptake and impact in the clinic. If we could then manage a spin-out with a good chance of survival every 2-3 years, we would be pretty happy.
We are certainly unique with respect to the involvement of clinicians in nanotechnology research -they were onboard from the very beginning of the planning for the LCN. One of the founding directors of the LCN is a physician and we take the hard matter-biomedical research interface very seriously. I think this is a major factor in how we are different. The typical interface for hard matter researchers with biomedicine is through biophysicists, rather than through individuals with actual experience of medical practice. The other thing to realize is that the UK is especially strong in medical research, while there are many centers elsewhere that are more prestigious in the physical sciences than we are. However, I do not feel we have as much competition in terms of our close clinical relationships, although other countries and institutes are moving rapidly in that direction.
Other unique features of the LCN are that many of our people have industry experience and that the program here revolves entirely around interdisciplinary research. We have a single mission to produce solutions in a variety of areas using nanotechnology.
It is sometimes difficult to encourage clinicians to become involved in nano-related research but, at the LCN, we have managed to create an environment where the clinicians and biologists feel comfortable enough to come in and teach us the things that we need to know. For us as scientists and engineers without medical training it is not really that big a stretch to research clinical applications when we are surrounded by people who are as close to medicine as our colleagues at the Imperial College and UCL medical schools. We have gone a long way to improving our own knowledge by having colleagues, such as Mike Horton and Chris Mason, who are medically trained and also interested in the physical and engineering sciences.
All those in the LCN, including those who worked here before I arrived, have bought into the concept of an interdisciplinary approach. So I would say that the management challenges have been more in dealing with the traditional structures of the university rather than with the individuals. The individuals have all bought into our interdisciplinary problem-rich environment.
In the future, will we see more researchers with specific 'nanotechnology' training? GA: Elsewhere, there are nanotechnology undergraduate degree programs that have actually rescued the university programs in physical sciences. The programs at Imperial and UCL could probably live without us but LCN staff are managing Masters training courses in nanomaterials and nanotechnology. So it is clear that we will be seeing more researchers with specific 'nanotechnology' training. Having said that, I have my own prejudices on education, whatever the specialization. The main ingredients for a successful career in nanotechnology or any other scientific, engineering or medical subject are understandings of how to keep a lab book, how to do mathematics and how to think logically. 
Launch of the London Centre for Nanotechnology -INTERVIEW
How important is the interface between academia and industry in nanomedicine? GA: It is extremely important to us and we have several ways in which we are involved with companies of various sizes. There are start-up companies that are growing out of the LCN but there are also consultancy companies bringing in people from the LCN on secondments.
In addition to Endomagnetics, we are actually forming another start-up company called the Bio Nano Centre. This is a prototyping and consulting company with an easy-to-use interface for industry. We believe that this is the first single organization that provides a seamless concept-to-market route for the emerging bionanotechnology sector, basically providing contracts with actual delivery dates and other enforceable terms for industry.
The LCN formed this company with the Institute for Biomedical Engineering at Imperial College and it makes use of the knowledge base as well as the facilities we have. The Bio Nano Centre will look to UCL and Imperial College for the expertise and facilities required by industrial partners but, if those capabilities are not available in a timely fashion, then they will outsource the work elsewhere, so that industry clients are not left high and dry because of shifting academic agendas.
The Bio Nano Centre offers concept development, rapid prototyping and product validation services, translating research concepts to trial-ready prototypes, ready for manufacture, in several seamless steps:
• Research and feasibility, including development and networking; • Bionano characterization, fabrication and concept trialing; • Concept development, including early medical input; • Rapid prototyping, including refinement; • Clinical access; • Commercialization and handover.
One of the main issues that we are trying to address with the Bio Nano Centre is to focus academic scientists who may not previously have worked along industry lines. I should also repeat that, at the LCN itself, many members of staff have come from industrial backgrounds. This means that there is generally more awareness of what the needs of industry are and also a business focus within the LCN. We have a full-time business development manager, which is unusual for an academic enterprise, working for the LCN itself and not the larger business development units of the two universities.
How does the mainstream scientific establishment view the potential of nanotechnology in medicine?
GA: There is fairly successful nanotechnology in place already in medicine. If you just look at the MRI contrast enhancers, then these are magnetic nanoparticles, already US FDA approved. How much more mainstream can you get than that? QP: Of course the funny thing is that most pharmaceutical molecules are much smaller than a nanoparticle.
GA: In some sense, nanotechnology, if you like, has been accepted in medicine already. It has just not been branded as such. It is not really a question of getting the establishment to 'accept it'; there is not a particular resistance or acceptance of nanotechnology any more than there is a particular resistance or acceptance of other emerging areas, such as regenerative medicine. If you talk to people in medicine, one group will say 'this is an area for the usual Charlatans to work in' whereas the other will say 'this is the best thing since sliced bread'. So there is a real diversity of opinions, although I think nanotechnology is different from stem cells in that there has already been FDA approval of certain nanotechnology-related diagnostics.
How would you define 'nanomedicine'? QP: When it comes to nanomedicine, I am not entirely sure that it is a useful word. It implies that there is something 'new' for medicine that was not there previously, which is a result of something happening at the nanometer scale. The scale is where the novelty lies; it lies in the sense that the word is an invitation to physical scientists, engineers and biologists, who are not normally allowed through the door of the medical practitioner's office, to actually get an opportunity to work with them to do something useful in terms of the biomedical applications of new technologies. This is when you start to get people who are willing to come together to explore some potential routes towards solutions for problems that have had longstanding histories. Then you get benefits.
In a sense, nanobiotechnology is like an umbrella, under which people who want to can all shelter and, under that common roof, work together.
It can sometimes be difficult, but my experience with Endomagnetics is that making the right links is the crucial thing -bringing together the people who want to work together but who do not normally talk to each other. It is a sociological thing.
What have been the most important milestones in the nanotechnology field? GA: Nanotechnology as we really understand it is defined by two things that distinguish it from molecular biology or from traditional physics. The first is the ability to scan and move atoms, using, essentially, scan probe microscopes. The second is the ability to fabricate macromolecules, especially quantum dots and carbon fullerenes. These are really the two main events -what I would call modern macromolecular chemistry, properly construed, and the modern scan probe. We are still working on their consequences and will be doing so for a while longer to come.
You could just look at what Professor Pankhurst described as functionalizing nanoparticles. This has a tremendous future because nanoparticles give you a 'handle' onto which you can attach biologically relevant substances. The handle has interesting optical, thermal, etc. properties, but is inert biologically apart 
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Launch of the London Centre for Nanotechnology -INTERVIEW from those physical properties. You can then attach a molecule whose other end can bind to an appropriate docking site in, for example, a diseased tissue, at which point you could start pumping energy through the handle and whatever else is required.
QP: The energy is a direct consequence of the magnetic or molecular or carbon-based nanoparticles. On the same level, the scan probe can also deliver energy, albeit more directly. This can then be applied to physiological questions and is extremely powerful. For example, Mike Horton has an extremely active research program looking at the mechanical responses of osteoblasts to stimulation on the nanometer level from a scan probe, to look at the signaling events.
GA: I broke my arm once, and the cast was extremely tight and now people have realized that this is the wrong thing to do because actually there is mechanical stimulation of bone regrowth. Mike Horton has studied this at the cellular level by using a scan probe microscope tip to stimulate the mechanical regrowth. Once you understand the systems biology of that at the nanoscale, you can go in and deal with pathologies and therapy or disease at the microscopic scale and then the scales of cell and animal physiology. That is one direct consequence of a tool that was designed originally to resolve issues in semiconductor physics 20 years ago. I think there are tremendous opportunities here and they are very distinct from, but greatly enhance, the opportunities that are presented by molecular biology. Nanotechnology is another tool kit, just as genetic engineering is a toolkit.
Where will the LCN focus over the next 5 years? GA: We see a lot of potential for using nanotechnology methods for high-throughput screening of biologically interesting substances, from molecules to entire cells. Together with biochemical engineers we are looking at making this type of screening more precise and more informative than it is today. Another project revolves around molecular recognition, where we are trying to do the science and engineering that would underpin the entry of cantilever sensors into the diagnostics market. One of the electrical engineers is an expert on diamond, which he is planning to exploit as a substrate for biocompatible electronics. We have physicists interested in new x-ray techniques that might eliminate the need for crystallization of proteins prior to structure determination, but would also extend the resolution of 'light' microscopy to the nanometer scale.
Beyond that, the list just goes on -we are seeing tremendous promise both in the basic science laboratories as well as on the medical side.
QP: Within Endomagnetics, we hope that, within 5 years, we will be selling our products. I can confidently say that we will know whether it is a successful commercialization project within that timescale. In terms of where I see the field going in the next 5 years, I see great potential, particularly from in vitro diagnostics and also imaging -these two areas are where the significant early headway will be made. The in vivo applications and the therapeutics of course will take longer because it takes more time to get through trials but I would expect to see some trials up and running, definitely with nanotechnology as one of their key features.
Finally, in the long term, how do you see the ultimate potential for nanomedicine? GA: I would quibble with this notion that nanomedicine is somehow separate from everything else we do in medicine. The ultimate goal for medicine is low-cost personalized healthcare. In addition, although I am not sure that all people want to live forever, politicians do, so we can help them with that. Nanotechnology is a key element in the tool kit required to achieve personalized medicine because, at the end of the day, our aim is to replace your GP with a cell phone. That is one ultimate goal of nanotechnology and there is no question that the associated sensors and intelligent therapeutic agents are going to use nanotechnology. There are many things in addition to nanotechnology that we have to deal with in making that dream a reality, however, and, although some could be obvious issues, such as pharmacology, others will be less obvious, such as cryptography. That is the broad vision for medicine -nanotechnology is simply one of the things that are needed to create the healthcare system of the future. 
